Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers

NACompletedINTERVENTIONAL
Enrollment

269

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Breast CancerOvarian CancerPancreatic CancerMetastatic Prostate Cancer
Interventions
BEHAVIORAL

Standard Genetic Counseling

Standard of care genetic counseling

BEHAVIORAL

Educational Video

Video tutorial about genetic testing

Trial Locations (6)

02215

Dana-Farber Cancer Institute, Boston

02135

Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton

01757

Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford

02190

Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, Weymouth

03053

Dana-Farber/New Hampshire Oncology-Hematology, Londonderry

02903

Lifespan Cancer Institute at Rhode Island Hospital, Providence

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ambry Genetics

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT04330716 - Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers | Biotech Hunter | Biotech Hunter